- Home
- LXEO vs PBYI Comparison
LXEO vs PBYI Comparison
Compare LXEO & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- PBYI
- Stock Information
- Founded
- LXEO 2017
- PBYI 2010
- Country
- LXEO United States
- PBYI United States
- Employees
- LXEO N/A
- PBYI N/A
- Industry
- LXEO
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- PBYI Health Care
- Exchange
- LXEO Nasdaq
- PBYI Nasdaq
- Market Cap
- LXEO 290.5M
- PBYI 237.2M
- IPO Year
- LXEO 2023
- PBYI N/A
- Fundamental
- Price
- LXEO $6.47
- PBYI $5.03
- Analyst Decision
- LXEO Strong Buy
- PBYI Strong Buy
- Analyst Count
- LXEO 7
- PBYI 1
- Target Price
- LXEO $15.29
- PBYI $7.00
- AVG Volume (30 Days)
- LXEO 763.8K
- PBYI 497.8K
- Earning Date
- LXEO 11-12-2025
- PBYI 11-06-2025
- Dividend Yield
- LXEO N/A
- PBYI N/A
- EPS Growth
- LXEO N/A
- PBYI 434.29
- EPS
- LXEO N/A
- PBYI 0.97
- Revenue
- LXEO N/A
- PBYI $238,062,000.00
- Revenue This Year
- LXEO N/A
- PBYI N/A
- Revenue Next Year
- LXEO N/A
- PBYI N/A
- P/E Ratio
- LXEO N/A
- PBYI $5.17
- Revenue Growth
- LXEO N/A
- PBYI 8.63
- 52 Week Low
- LXEO $1.45
- PBYI $2.32
- 52 Week High
- LXEO $11.72
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- LXEO 67.21
- PBYI 56.56
- Support Level
- LXEO $6.33
- PBYI $4.95
- Resistance Level
- LXEO $6.90
- PBYI $5.45
- Average True Range (ATR)
- LXEO 0.51
- PBYI 0.26
- MACD
- LXEO 0.05
- PBYI 0.04
- Stochastic Oscillator
- LXEO 62.04
- PBYI 63.48
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.